| Literature DB >> 34750457 |
Kunzhi Chen1,2,3, Zhuangzhuang Zheng1,2,3, Lijuan Ding1,2,3, Na Tao4, Libo Wang1,2,3, Wenming Xia1,2,3, Huidong Wang1,2,3, Xin Jiang5,6,7.
Abstract
Radiotherapy (RT) is one of the main treatment strategies of breast cancer. It is challenging to design RT plans that can completely cover the target area while protecting organs at risk (OAR). The Plan-IQ feasibility tool can estimate the best sparing dose of OAR before optimizing the Plan. A systematic quantitative evaluation of the quality change of intensity-modulated radiation therapy (IMRT) using the Plan-IQ feasibility tool was performed for modified radical mastectomy in this study. We selected 50 patients with breast cancer treated with IMRT. All patients received the same dose in the planning target volume (PTV). The plans are categorized into two groups, with each patient having one plan in each group: the clinically accepted normal plan group (NP group) and the repeat plan group (RP group). An automated planning strategy was generated using a Plan-IQ feasibility dose volume histogram (FDVH) in RP group. These plans were assessed according to the dosimetry parameters. A detailed scoring strategy was based on the RTOG9804 report and 2018 National Comprehensive Cancer Network guidelines, combined with clinical experience. PTV coverage in both groups was achieved at 100% of the prescribed dose. Except for the thyroid coverage, the dose limit of organs at risk (OAR) in RP group was significantly better than that in NP group. In the scoring analysis, the total scores of RP group decreased compared to that of NP group (P < 0.05), and the individual scores of PTV and OAR significantly changed. PTV scores in RP group decreased (P < 0.01); however, OAR scores improved (P < 0.01). The Plan-IQ FDVH was useful for evaluating a class solution for IMRT planning. Plan-IQ can automatically help physicians design the best OAR protection plan, which sacrifices part of PTV, but still meets clinical requirements.Entities:
Mesh:
Year: 2021 PMID: 34750457 PMCID: PMC8575920 DOI: 10.1038/s41598-021-01305-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Dosimetry comparison for the PTV of RP group and NP group (mean ± SD).
| PTV | n | RP group | NP group | t | |
|---|---|---|---|---|---|
| VRX | 50 | 94.37 ± 0.88 | 94.79 ± 0.93 | − 4.57 | |
| CI | 50 | 0.66 ± 0.05 | 0.72 ± 0.04 | − 12.99 | |
| HI | 50 | 0.13 ± 0.02 | 0.1 ± 0.02 | − 6.14 | |
| V55 | 50 | 1.97 ± 1.82 | 0.19 ± 0.31 | − 6.14 | |
| Dmean | 50 | 52.45 ± 0.33 | 51.9 ± 0.24 | − 6.14 |
*a = Paired t test, *b = Nonparametric Wilcoxon test, P < 0.05.
Bold values indicates that the difference is statistically significant (P<0.05)
Figure 1Dosimetry comparison for the PTV of RP group and NP group. VRX of the NP group was higher than that of the RP group (t = − 4.57, P < 0.01) (a). CI and HI of NP group was higher than that of RP group (t = − 12.99, P < 0.01; t = − 6.14, P < 0.01) (b). V55 and Dmean of the RP group were higher than that of NP group (t = − 6.14, P < 0.01; t = − 6.14, P < 0.01) (a,c). *P < 0.05.
Figure 2The FDVH diagram of ipsilateral lung. The green region was considered dosimetrically easy to achieve, yellow was more challenging, orange is difficult, and the red region indicates an region which cannot be achieved. The gray line represents the FDVH curve of the affected lung of NP group, while the dashed line represents the FDVH curve of the affected lung of RP group when F is 0.12. The V20 in the yellow region of great concern in RP group is significantly lower than that of NP group.
Dosimetry comparison for the OAR of RP group and NP group (mean ± SD) (cGy).
| OAR | n | RP group | NP group | t | ||
|---|---|---|---|---|---|---|
| Ipsilateral lung | V20Gy | 50 | 19.56 ± 2.4 | 22.1 ± 2.06 | − 6.15 | |
| V10Gy | 50 | 31.01 ± 3.06 | 32.16 ± 2.84 | − 4.20 | ||
| V5Gy | 50 | 45.83 ± 4.56 | 44.9 ± 3.48 | 2.38 | ||
| Dmean | 50 | 10.68 ± 1.09 | 11.45 ± 1.02 | − 6.14 | ||
| Heart | Dmean | 50 | 4.95 ± 1.72 | 5.38 ± 1.88 | − 3.68 | |
| Breast-R | Dmean | 50 | 11.19 ± 7.17 | 17.27 ± 12 | − 4.79 | |
| Spinal cord | Dmax | 50 | 13.62 ± 3.16 | 22.67 ± 5.7 | − 6.02 | |
| shoulder joint-L | Dmean | 50 | 7.93 ± 2.2 | 12.38 ± 2.53 | − 15.34 | |
| Dmax | 50 | 20.06 ± 7.84 | 32.63 ± 7.74 | − 13.71 | ||
| Thyroid | Dmean | 50 | 15.25 ± 4.82 | 14.6 ± 4.93 | − 1.38 | 0.17b |
| Dmax | 50 | 47.26 ± 8.9 | 45.47 ± 7.89 | − 3.66 | ||
| Trachea | Dmean | 50 | 6.79 ± 2.04 | 7.51 ± 3.25 | − 2.48 | |
| Dmax | 50 | 19.83 ± 8.46 | 22.85 ± 10.11 | − 4.02 | ||
| Esophagus | Dmean | 50 | 3.94 ± 1.88 | 4.3 ± 2.55 | − 1.68 | |
| Dmax | 50 | 28.89 ± 12.76 | 30.78 ± 12.41 | − 2.06 | 0.05a | |
| Intestines | Dmean | 50 | 7.59 ± 5.85 | 12.46 ± 10.89 | − 4.53 | |
| Dmax | 50 | 32.58 ± 19.06 | 36.84 ± 18.78 | − 2.15 | ||
*a = Paired t test, *b = Nonparametric Wilcoxon test, P < 0.05.
Bold values indicates that the difference is statistically significant (P<0.05)
Dosimetry comparison for the MU of RP group and RP group (mean ± SD).
| Group | n | MU |
|---|---|---|
| RP group | 50 | 899.7 ± 120.89 |
| NP group | 50 | 752.34 ± 111.43 |
| t | 10.65 | |
*a = Paired t test, P < 0.05.
Bold values indicates that the difference is statistically significant (P<0.05)
Evaluation comparison for the score of RP group and NP group (mean ± SD).
| Structure | NP group | RP group | ||
|---|---|---|---|---|
| Total score | 107.00 ± 13.13 | 104.37 ± 12.64 | − 2.486 | |
| PTV score | 47.99 ± 3.91 | 37.72 ± 6.52 | − 6.144 | |
| OAR score | 59.01 ± 11.41 | 66.65 ± 8.10 | − 6.028 |
*a = Paired t test, Wilcoxon test, P < 0.05.
Bold values indicates that the difference is statistically significant (P<0.05)